Bob Mauch

Bob Mauch
Born	Robert P. Mauch
Nationality	American
Occupation	Corporate executive, pharmacist
Title	President and Chief Executive Officer, Cencora, Inc.
Known for	President and CEO of Cencora, Inc. (formerly AmerisourceBergen)
Education	PharmD, PhD

Robert P. Mauch, PharmD, PhD, is an American corporate executive and pharmacist serving as President and Chief Executive Officer of Cencora, Inc. (NYSE: COR). The company ranks among the largest pharmaceutical distribution operations in the United States. Cencora, which operated as AmerisourceBergen until its 2023 rebranding, is a Fortune 500 company central to the pharmaceutical supply chain. It distributes drugs to pharmacies, hospitals, and healthcare providers across the United States and internationally. Mauch took over as President and CEO in October 2024, replacing Steven H. Collis, who moved into the role of executive chairman.

Before this promotion, Mauch served as Chief Operating Officer, overseeing the company's pharmaceutical distribution operations and strategic initiatives. A trained pharmacist with both a Doctor of Pharmacy (PharmD) and Doctor of Philosophy (PhD), he'd spent much of his career in the pharmaceutical distribution industry, working up through various leadership positions. His appointment showed the company's focus on leadership continuity and operational expertise during a period of major change in the pharmaceutical supply chain.

Education

Mauch holds advanced degrees in pharmaceutical sciences. He earned a Doctor of Pharmacy (PharmD) degree and a Doctor of Philosophy (PhD). This dual doctoral-level education in pharmacy distinguishes him among pharmaceutical industry executives. His academic grounding runs deep in the science and practice of pharmacy, which shaped his approach to leading one of the nation's largest drug distribution enterprises. Professional profiles cite his academic background as underpinning his understanding of the pharmaceutical products and healthcare systems that Cencora serves.

Career

Rise within Cencora

Mauch held the position of Chief Operating Officer (COO) at Cencora before becoming CEO. In that role, he oversaw the company's core pharmaceutical distribution operations. One of the largest networks of drug distribution centers in the United States fell under his purview. The COO position put him at the heart of the company's day-to-day operations and strategic planning. He had direct oversight of the infrastructure, logistics, and partnerships that form the backbone of Cencora's business model.

Cencora operated under the name AmerisourceBergen until its 2023 rebranding. It's one of the "Big Three" pharmaceutical distributors in the United States, alongside McKesson and Cardinal Health. The company distributes branded and generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies to a broad range of healthcare providers. Mauch's tenure in the COO role made him the natural successor to Steven Collis, who'd served as CEO since 2011.

Appointment as President and CEO

Cencora announced its leadership succession plan on March 12, 2024. Mauch would succeed Steven H. Collis as President and Chief Executive Officer under the plan. Collis was to transition to executive chairman of Cencora's board of directors. Mauch would assume the top executive position and be appointed as a board member.

Multiple news outlets covered the announcement. The Philadelphia Inquirer described Cencora as "among the largest pharmaceutical distributors in the United States" and noted that Mauch had been selected to lead during a period of ongoing change in the healthcare and pharmaceutical industries. Drug Store News characterized the transition as reflecting the company's commitment to leadership continuity. Collis would stay involved as executive chairman while Mauch took operational control.

Mauch officially took the helm as President and CEO in October 2024. The Business Roundtable, of which he became a member, described him as being "focused on building on" the company's existing strategy and furthering its role in the pharmaceutical supply chain.

First Year as CEO

Mauch's first year leading Cencora was marked by significant strategic and operational developments. In an October 2025 interview with Pharmaceutical Executive, he discussed lessons from his initial year as CEO and addressed the complex challenges facing pharmaceutical distribution. Supply chain resilience, regulatory pressures, and the evolving landscape of specialty and biosimilar drugs all came up.

A December 2025 feature in Modern Healthcare captured his thinking on pharmaceutical distribution modernization. He discussed the company's efforts to deliver medicines to patients more efficiently. He also talked about introducing innovations that reduce the time required to bring treatments from manufacturers to the point of care. Cencora's evolution was characterized as moving "from warehouse to wellness," reflecting the company's expanding role beyond traditional drug warehousing and logistics into patient services and healthcare innovation.

Major Investment and Financial Performance

One of the most significant announcements during Mauch's tenure came in November 2025. Cencora disclosed plans to invest over $1 billion through 2030 to expand its U.S. drug distribution network. Reuters reported the investment as part of the company's strategy to strengthen its infrastructure in response to growing demand for pharmaceutical distribution services. The move aimed to increase the capacity and efficiency of its facilities across the country.

The billion-dollar investment plan came alongside the company's fiscal year 2025 fourth quarter and full-year financial results. A Business Wire press release dated November 5, 2025 reported that Cencora's revenue in its fiscal year 2025 fourth quarter (ended September 30, 2025) increased 5.9 percent compared to the prior year period. The company also issued an upbeat forecast for fiscal year 2026, signaling confidence in the trajectory of its business under Mauch's leadership.

Strong revenue growth combined with a forward-looking infrastructure investment plan positioned Cencora as an aggressive competitor in the pharmaceutical distribution sector. The $1 billion investment signaled the company's commitment to expanding its physical distribution capabilities. This came at a time when the pharmaceutical industry was grappling with increasing complexity in drug supply chains. Specialty pharmaceuticals, cell and gene therapies, and temperature-sensitive biologics were all driving change.

Industry Context

Mauch took the CEO role during significant industry upheaval. The three largest U.S. drug distributors are Cencora, McKesson, and Cardinal Health. They collectively handle the vast majority of pharmaceutical products distributed in the country. These companies serve as the critical link between drug manufacturers and the pharmacies, hospitals, and health systems that dispense medications to patients.

The industry faced scrutiny in recent years. Drug pricing pressures, the opioid crisis, and the complexities of distributing increasingly specialized therapies all created challenges. Cencora, under its previous name AmerisourceBergen, reached settlement agreements related to opioid-related litigation. Industry media characterized Mauch's leadership as focused on strengthening the supply chain, investing in technology and infrastructure, and positioning Cencora to handle the next generation of pharmaceutical products, including biosimilars and advanced therapies.

The Pharmaceutical Executive profile of Mauch in October 2025 explored his perspective on "tackling a complex future for pharma distribution." He emphasized operational resilience and adaptability as key priorities. In the Modern Healthcare interview, Mauch described innovations within Cencora's operations aimed at cutting the time it takes to bring treatments to patients. This reflected a broader industry trend toward speed, precision, and patient-centered distribution models.

Professional Affiliations

In October 2024, when he took the CEO role, Mauch was listed as a member of the Business Roundtable. This association brings together chief executive officers of leading American companies. The Business Roundtable profile described him as President and Chief Executive Officer of Cencora, Inc., and noted his academic credentials. Business Roundtable membership places him among a group of CEOs who collectively lead companies with more than 20 million employees and more than $10 trillion in annual revenues. These CEOs participate in policy discussions on economic and business issues at the national level.

Recognition

Selection as CEO of Cencora represented a significant professional milestone. The company ranks as one of the largest corporations in the United States by revenue. The succession announcement received coverage in major business and healthcare publications, including The Philadelphia Inquirer, Drug Store News, and citybiz.

His interviews and profiles in Pharmaceutical Executive and Modern Healthcare during 2025 positioned him as one of the most prominent voices in the pharmaceutical distribution industry that year. The Modern Healthcare feature, published in December 2025, highlighted his leadership in modernizing drug distribution. It focused on his commitment to patient-centered innovation within the supply chain. The Pharmaceutical Executive profile, published in October 2025, examined his strategic vision during his first year as CEO. It explored his approach to navigating the evolving challenges of the pharmaceutical industry.

Strong financial performance under his leadership reinforced his standing. The 5.9 percent revenue increase in the fiscal 2025 fourth quarter and the announcement of a $1 billion infrastructure investment both mattered. He'd established himself as a significant figure in the healthcare business world.

Legacy

As of the end of fiscal year 2025, Mauch's tenure as CEO had just begun in October 2024. Still, several defining elements of his leadership had already emerged. The announcement of the $1 billion investment in U.S. drug distribution infrastructure through 2030 represented one of the most significant capital commitments in the company's recent history. It signaled a long-term strategic direction under his leadership.

His public interviews emphasized the evolving role of pharmaceutical distributors. It's not just about simple logistics anymore. His characterization of Cencora's mission as moving "from warehouse to wellness" reflected an industry-wide shift in which distributors increasingly participate in patient services, data analytics, and the management of complex therapy supply chains. His dual doctoral credentials in pharmacy provide a distinctive perspective among major drug distribution company leaders. They ground his strategic decisions in a deep understanding of pharmaceutical science and healthcare delivery.

Cencora is headquartered in Conshohocken, Pennsylvania. It remains one of the largest companies in the Philadelphia metropolitan area. It's among the most significant players in global pharmaceutical distribution. Mauch's leadership places him at the intersection of healthcare, logistics, and corporate strategy at a crucial moment for the pharmaceutical industry.